Dupilumab Resolves Airway Mucus Plugs and Reduces Radiodensity in Asthma

The Radiographic Challenge of Airway Mucus Plugging

In patients with moderate-to-severe asthma, chronic airway inflammation often leads to the formation of occlusive mucus plugs that contribute to persistent airflow obstruction and increased exacerbation risk [1, 2]. These plugs are frequently associated with type 2 inflammation, characterized by elevated blood eosinophils and fractional exhaled nitric oxide [3, 4]. While interleukin-4 and interleukin-13 antagonists like dupilumab have demonstrated efficacy in improving forced expiratory volume and reducing the need for oral corticosteroids, the physical resolution of these airway obstructions remains a primary clinical goal [5, 6]. Traditional assessments have focused on global lung function, yet localized ventilation defects often persist despite standard therapy [2, 7]. A new study now offers fresh insights into the longitudinal behavior and structural changes of individual mucus plugs under biologic treatment.

Longitudinal Tracking of Airway Obstructions

The researchers evaluated a cohort of 32 adults with moderate-to-severe asthma to determine how biologic therapy influences the physical characteristics and behavior of airway obstructions. Within this study population, 22 participants received dupilumab, an interleukin-4 and interleukin-13 antagonist, which was administered every 2 weeks for a duration of at least 16 weeks. The remaining 10 participants served as the control group, providing a comparative baseline for assessing the natural progression of mucus plugging versus the effects of targeted cytokine inhibition. To quantify changes in airway pathology, the authors utilized computed tomography (CT) scans acquired at baseline and follow-up to evaluate individual plug count, volume, and radiodensity, which is the physical density of the material as measured by X-ray attenuation. By tracking these obstructions longitudinally, the researchers were able to categorize each plug into one of three distinct states: resolved (plugs that disappeared by the follow-up scan), fixed-location persistent (plugs that remained in the same anatomical position throughout the study), or new-onset (plugs that were absent at baseline but appeared during the treatment period). This granular mapping allowed the team to move beyond global lung function metrics and observe the specific fate of localized obstructions under the influence of dupilumab, providing a more detailed view of how biologics modify the internal architecture of the asthmatic lung.

Impact on Mucus Volume and Pulmonary Function

The clinical utility of dupilumab in managing moderate-to-severe asthma is underscored by its ability to physically alter the landscape of the airways. The researchers found that post-dupilumab reductions in mucus score, total mucus plug count, and total plug volume were significantly greater than those observed in the control group (p < 0.05). This reduction in the physical burden of disease was not merely a radiographic observation but translated directly into measurable physiological gains for the patients. Specifically, the reductions in mucus burden were associated with improved forced expiratory volume in 1 second (FEV1) (p < 0.05), indicating that the clearance of these obstructions directly facilitates better airflow during the first second of a forced exhalation. Beyond simple volume metrics, the study demonstrated that the resolution of mucus plugs correlated with broader improvements in lung mechanics and gas distribution. The reductions in mucus burden were associated with an improved FEV1/FVC ratio (p < 0.05), a key clinical indicator used to assess the severity of airway obstruction. Furthermore, the researchers utilized 129Xe magnetic resonance imaging ventilation defect percent (a specialized imaging metric that quantifies areas of the lung not receiving air) to assess regional lung function. They determined that reductions in mucus burden were associated with improved 129Xe magnetic resonance imaging ventilation defect percent (VDP) (p < 0.05). This finding suggests that as dupilumab clears mucus plugs, it restores ventilation to previously obstructed segments of the lung, thereby reducing the total volume of lung tissue that is functionally bypassed during respiration, a critical factor in reducing patient dyspnea and improving exercise tolerance.

Resolution Rates and Prevention of New Plugs

The longitudinal analysis of individual mucus plugs reveals a significant shift in the airway landscape for patients receiving dupilumab. The researchers found that 36% of dupilumab-treated participants achieved complete resolution of mucus plugs, a rate more than triple the 10% observed in the control group. While complete clearance was more common in the treatment arm, 59% of dupilumab-treated participants had incomplete resolution of mucus plugs, compared to 80% of those in the control group. These findings suggest that while dupilumab effectively reduces the total burden of airway obstruction, a subset of patients may require longer treatment durations or additional interventions to achieve entirely clear airways. When examining the fate of individual obstructions, the study demonstrated that dupilumab-treated participants had more resolved plugs than controls (91% vs. 58%, p < 0.0001). This high rate of clearance was accompanied by a substantial reduction in fixed-location persistent plugs, which are mucus obstructions that remain in the same anatomical position over multiple scans. Specifically, dupilumab-treated participants had fewer fixed-location persistent plugs than controls (9% vs. 42%, p < 0.0001). For the clinician, this indicates that dupilumab is highly effective at mobilizing and clearing established mucus that would otherwise remain stationary and contribute to chronic regional ventilation defects. Beyond the resolution of existing obstructions, the therapy appears to alter the underlying pathophysiology that leads to new mucus formation. The researchers observed that dupilumab-treated participants had fewer new-onset plugs than controls, with a median of 1 (range 0 to 5) new plug compared to a median of 6 (range 0 to 18) in the control group (p = 0.0008). This reduction in the development of new obstructions, combined with the 91% resolution rate of existing plugs, suggests that interleukin-4 and interleukin-13 antagonism addresses both the current physical manifestations of the disease and the ongoing inflammatory processes that drive mucus hypersecretion and plugging.

Changes in Plug Composition and Clinical Significance

Beyond reducing the total number of obstructions, dupilumab appears to alter the physical composition of the mucus that remains in the airways. The researchers quantified these changes using Hounsfield Units (HU), a standardized scale of radiodensity where lower values indicate less dense material, such as air or fat, and higher values indicate denser material, such as bone or thick fluid. For patients receiving dupilumab, the radiodensity of fixed-location persistent plugs decreased from -422 HU (range -759 to -5) at baseline to -569 HU (range -738 to -258) at follow-up (p = 0.009). This shift toward lower radiodensity suggests that even when a plug does not fully resolve, the treatment may modify its structural characteristics, potentially making the mucus less viscous or less obstructive to airflow. A similar pattern of reduced density was observed in the formation of new obstructions. The new-onset plugs in the dupilumab group had significantly lower radiodensity compared to those in the control group, measuring -573 HU (range -765 to -320) versus -387 HU (range -662 to -26) (p = 0.0006). Despite these physical changes, residual obstructions continue to impact pulmonary physiology. The study found that participants with incomplete resolution had persistently higher ventilation defect percent (VDP) compared to those with complete resolution (p < 0.05), as measured by 129Xe magnetic resonance imaging. These findings indicate that residual low-radiodensity persistent and new-onset plugs remain functionally relevant to the patient's respiratory status, underscoring the clinical importance of achieving total clearance of airway mucus to fully optimize lung ventilation and highlighting that even "thinner" mucus can still impair gas exchange.

References

1. Agache I, Beltrán J, Akdiş CA, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy. 2020. doi:10.1111/all.14221

2. Aegerter H, Brightling CE, Dunican EM, et al. Effectiveness of biologics for reducing occlusive mucus plugs in patients with severe asthma: a systematic review.. Respiratory research. 2026. doi:10.1186/s12931-026-03501-z

3. Castro M, Papi A, Porsbjerg C, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.. The Lancet Respiratory Medicine. 2025. doi:10.1016/s2213-2600(24)00362-x

4. Phinyo P, Krikeerati T, Vichara-Anont I, Thongngarm T. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.. The journal of allergy and clinical immunology. In practice. 2024. doi:10.1016/j.jaip.2023.11.007

5. Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials.. The Journal of asthma : official journal of the Association for the Care of Asthma. 2019. doi:10.1080/02770903.2018.1520865

6. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.. Allergy. 2020. doi:10.1111/all.14268

7. Porsbjerg C, Dunican E, Lugogo N, et al. Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial.. American Journal of Respiratory and Critical Care Medicine. 2025. doi:10.1164/rccm.202410-1894OC